OBJECTIVE: To investigate the prognostic value of HER2 and p63 expression in head and neck squamous cell carcinoma (HNSCC).
STUDY DESIGN: A case review of 186 HNSCCs from the oral tongue, palate, maxillary sinus, floor of mouth, oropharynx, hypopharynx, and larynx.
SUBJECTS AND METHODS: All primary tumor specimens were evaluated by immunohistochemistry for HER2 and p63 expressions, which were correlated with clinical parameters including age, sex, grade, lymph node metastases, stage, and survival.
RESULTS: One hundred forty-one patients had stage III-IV disease and 109 had lymph node metastases. For all cases, T and N stages were significant prognostic predictors for both overall and disease-free survivals. In the node-positive subgroup, T stage and HER2 expression were significant prognostic predictors for both overall and disease-free survivals.
CONCLUSION: HER2 may be associated with longer survival in node-positive patients with HNSCC.
Get full access to this article
View all access options for this article.
References
1.
CroweDLHaciaJGHsiehCL, et al. Molecular pathology of head and neck cancer. Histol Histopathol2002;17:909–14.
2.
TakedaTSugiharaKHirayamaY, et al. Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med2006;35:369–75.
3.
ZangenRRatovitskiESidranskyD.DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle2005;4:1313–5.
4.
RoccoJWLeongCOKuperwasserN, et al. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell2006;9:45–56.
5.
MichaudWANicholsACMrozEA, et al. Bcl2 blocks cisplatin induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res2009;15:1645–54.
6.
KhademiBShiraziFMVaseiM, et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett2002;184:223–30.
7.
AkamatsuMMatsumotoTOkaK, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys2003;57:1323–7.
8.
KhanAJKingBLSmithBD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res2002;8:540–8.
9.
FongYChouSJHungKF, et al. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. J Chin Med Assoc2008;71:123–7.
10.
CavalotAMartoneTRoggeroN, et al. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck2007;29:655–64.
11.
Parise JuniorOCarvalhoLVMiguelRE, et al. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma. Sao Paulo Med J2004;122:264–8.
12.
YuDWangSSDulskiKM, et al. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res1994;54:3260–6.
13.
SpencerKSGraus-PortaDLengJ, et al. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol2000;148:385–97.
14.
O-charoenratPRhys-EvansPHModjtahediH, et al. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol2002;38:627–40.
15.
RaitASPirolloKFUlickD, et al. HER-2 targeted antisense oligo-nucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann New York Acad Sci2003;1002:78–89.
16.
BortoluzziMCYurgelLSDekkerNP, et al. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2004;98:698–704.
17.
BarbieriCETangLJBrownKA, et al. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res2006;66:7589–97.
18.
RoccoJWEllisenLW.p63 and p73: life and death in squamous cell carcinoma. Cell Cycle2006;5:936–40.
19.
ThurfjellNCoatesPJVojtesekB, et al. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med2005;16:1065–70.
